B+
Bull case
30%
Probability
Target price
$270.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
DHR
DanaherANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q3 adjusted EPS of $2.11 beat the reported $1.92 consensus, while management raised full-year adjusted EPS guidance. Subsequent October 22 target increases were reported for Citi ($230 to $270), TD Cowen ($255 to $270) and Stifel ($220 to $260); these are target revisions, not evidence that forward earnings estimates rose.
Posture
Constructive
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-10-27.
What can break
Masimo and StatLab integration and acquisition-financing returns remain execution risks; the prior baseline's pending-close framing is stale relative to the supplied October 2026 10-Q excerpts.
Momentum
89
Value
60
Sentiment
66
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $249.00 · Bull $270.00 · Bear $195.00Analysis 2026-10-26; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-26 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $259.95
Why
Momentum89 · Δ7d -13.1
Value60 · Δ7d -0.2
Sentiment66 · Δ7d +34.9
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-27.
- • Sentiment remains the lead driver in the composite, 7D delta +34.9.
Contradictions & invalidation
- • Masimo and StatLab integration and acquisition-financing returns remain execution risks; the prior baseline's pending-close framing is stale relative to the supplied October 2026 10-Q excerpts.
- • Respiratory testing remains a drag: fourth-quarter guidance implies roughly 3% total core growth versus 4%–5% excluding respiratory revenue. [#SEC-8K-2026-10-21]
- • Reported core growth was only 3% including respiratory revenue, versus 5.5% excluding it.
Catalyst clock
2026-11-20
Q3 beat-and-raise follow-through
Lead driver: Sentiment · See AI snapshot
Momentum
89
8% active weight
Current posture
7d trendSoftening
Δ7d
-13.1
Δ21d
-0.2
Value
60
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.9
Sentiment
66
45% active weight
Current posture
7d trendImproving
Δ7d
+34.9
Δ21d
+27.7
Why this grade
Composite grade A. Momentum 89.4 / Value 60.4 / Sentiment 66.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-26. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$249.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$195.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$163.22B
Beta
0.92
Shares Out
703.53M
P/E (TTM)
48.4
P/S (TTM)
6.85
P/FCF (TTM)
39.87
Rev YoY
+5.5%
EPS YoY
+59.3%
Gross Margin
+59.0%
Op Margin
+21.2%
Net Debt
$15.08B
Current Ratio
1.65
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data